Revance Therapeutics — Technical Presentation (October 2020)
28 slides from Revance Therapeutics's technical presentation, Oct 14, 2020
Slide 1: ASPEN-1 Phase 3 Results: DaxibotulinumtoxinA for Injection
. Exhibit 99.2 @* revance ASPEN ® Phase 3 Results DaxibotulinumtoxinA for Injection ASPEN-1 PRESENTATION OCTOBER 14, 2020
Slide 2: Forward-Looking Statements Safe Harbor / Market Data
Forward-Looking Statements Safe Harbor / Market Data This presentation contains forward-looking statements, including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to: DaxibotulinumtoxinA potential for the treatment of
Slide 3: Positive Top-Line Results from Phase 3 Trial in Cervical Dystonia
First Phase 3 readout for DaxibotulinumtoxinA for Injection in a therapeutic indication. DaxibotulinumtoxinA for Injection could represent an important advancement in cervical dystonia care for suffering patients. DaxibotulinumtoxinA for Injection treatment effect shows consistent long duration acro
Slide 4: Cervical Dystonia Landscape
Cervical Dystonia Landscape Cervical dystonia - (also referred to as spasmodic torticollis) – is a painful chronic condition in which the neck muscles contract involuntarily, causing abnormal movements and awkward posture of the head and neck.1 Botulinum neurotoxins (BoNT) are the standard of care f
Slide 5: Duration Is a Key Unmet Need; Challenges With Currently Available BoNTs
In a recent survey of 209 respondents with cervical dystonia, 88% reported the reappearance of pre-existing symptoms between their botulinum toxin injections.6 Significant impact on professional and personal lives. 71% of patients would like longer-lasting benefits from neuromodulator treatments.6 D
Slide 6: Phase 3 Results of DaxibotulinumtoxinA in Cervical Dystonia
Phase 3 Results of DaxibotulinumtoxinA for Injection in CERVICAL DYSTONIA Presented By Roman G. Rubio, MD Senior Vice President Of Clinical Development
Slide 7: Phase 3 Randomized Placebo-Controlled Trial in Adults with Cervical Dystonia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Trial to Evaluate the Efficacy and Safety of a Single Treatment of DaxibotulinumtoxinA for Injection in Adults with Cervical Dystonia
Slide 8: Phase 3 Top-Line Results Summary
Phase 3 Top-Line Results Demonstrated that DaxibotulinumtoxinA for Injection, at either 125U or 250U, was an effective and generally well-tolerated treatment for reducing the signs and symptoms for cervical dystonia with up to a median duration of 24 weeks. DaxibotulinumtoxinA appeared to be general
Slide 9: Phase 3 Study Endpoints
Phase 3 Study Endpoints PRIMARY ENDPOINT: * Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) SECONDARY ENDPOINTS Duration of effect, defined as time from treatment to loss of ≥ 80% of peak treatment effect achieved at Weeks 4 and 6 (i.e. target TWSTRS Total Score) Change from baseline in
Slide 10: Study Design
Study Design Evaluating Subjects Over 36 Weeks Across 60 Sites In US, Canada And EU Phase 3, Single Dose, Randomized, Double Blind, Placebo-controlled Study ADULTS WITH MODERATE TO SEVERE CERVICAL DYSTONIA N = 301 18 to 80 years of age Moderate to Severe CD: TWSTRS Total ≥ 20 Toxin-naïve or experien
Slide 11: Demographics and Baseline Characteristics
Placebo (n=46) 125U (n=125) 250U (n=130) Total (n=301) DEMOGRAPHICS Female (n, %) 29 (63.0) 87 (69.6) 79 (60.8) 195 (64.8) AGE (years) mean (SD) range (min, max) 56.5 (11.8) 29, 80 57.2 (13.4) 18, 80 58.6 (10.6) 30, 79 57.7 (12.0) 18, 80 RACE (n, %) White 43 (93.5) 119 (95.2) 125 (96.2) 287 (95.3) B
Slide 12: Primary Endpoint Met for Both Doses
Primary Endpoint Met for Both 125 U and 250 U Doses AVERAGE CHANGE FROM BASELINE IN TWSTRS TOTAL SCORE AT WEEKS 4 AND 6 ∆=12% ∆=31% ∆=27% Placebo (n=46) DAXI 125 U (n=125) DAXI 250 U (n=130) Primary Analysis** p<0.0001 (125 U vs. Placebo) p=0.0006 (250 U vs. Placebo) p=0.1902 (250 U vs. 125 U) * Lea
Slide 13: Secondary Endpoint: Median Duration of Effect
Secondary Endpoint: Median Duration of Effect was 24 Weeks for 125 U Dose and 20 Weeks for 250 U Dose MEDIAN TIME TO LOSS OF ≥ 80% OF PEAK TREATMENT EFFECT
Slide 14: Duration of Effect for DAXI, BOTOX and Myobloc
Duration of Effect for DaxibotulinumtoxinA for Injection, BOTOX® and Myobloc® DaxibotulinumtoxinA for Injection Figure 2. from Comella 2005 All subjects had previous successful treatment with BoNTA, with a subjective report of at least 30% benefit. BOTOX ® AND MYOBLOC ® Note: Results drawn from mult
Slide 15: Secondary Endpoints: Clinical and Patient Global Impression of Change
Secondary Endpoints – Clinical and Patient Global Impression of Change Consistent* at Week 4 or 6 *Response of moderately better or very much better at Weeks 4 or 6. Subjects missing response on study defined as non-responder. PATIENT GLOBAL IMPRESSION OF CHANGE (PGIC) p<0.0001 (125 U vs. Placebo) p
Slide 16: TWSTRS Subscales Highly Consistent With Primary Endpoint
AVERAGE CHANGE FROM BASELINE AT WEEKS 4 AND 6 TWSTRS Subscales Highly Consistent With Primary Endpoint p<0.0001 (125 U vs. Placebo) p=0.0003 (250 U vs. Placebo) p=0. 2966 (250 U vs. 125 U) p<0.0001 (125 U vs. Placebo) p=0.0016 (250 U vs. Placebo) p=0. 3367 (250 U vs. 125 U) p<0.0007 (125 U vs. Place
Slide 17: Duration Achieved with Low Amount of Core Neurotoxin; Dysphagia Rate
DaxibotulinumtoxinA for Injection Duration Achieved with Low Amount of Core Neurotoxin Product, dose Dysphagia Rate DAXI 125U 1.6% DAXI 250U 3.9% Xeomin 120U 13%3 Dysport 500U 15%4 Xeomin 240U 18%3 Botox 236U 19%2 Field, et al. AbobotulinumtoxinA (Dysport®), OnabotulinumtoxinA (Botox®), and Incobotu
Slide 18: Safety: Treatment-Emergent Adverse Events Overall Summary
AE Summary n (%) # of Events Placebo (N=46) DAXI 125U (N=127) DAXI 250U (N=128) Total N=301) SUBJECTS WITH ANY TEAEs 18 ( 39.1) 34 74 ( 58.3) 148 64 ( 50.0) 134 156 ( 51.8) 316 SUBJECTS WITH ANY SERIOUS TEAEs* 0 5 ( 3.9) 5 3 ( 2.3) 4 8 ( 2.7) 9 SUBJECTS WITH ANY TREATMENT-RELATED TEAEs 8 ( 17.4) 11
Slide 19: Treatment-Related Adverse Events by Preferred Term
AE Summary n (%) Placebo (N=46) DAXI 125 U (N=127) DAXI 250 U (N=128) Total (N=301) SUBJECTS WITH ANY TREATMENT-RELATED TEAE 8 ( 17.4) 37 ( 29.1) 31 ( 24.2) 76 ( 25.2) Injection site pain 2 ( 4.3) 10 ( 7.9) 6 ( 4.7) 18 ( 6.0) Headache 1 ( 2.2) 6 ( 4.7) 6 ( 4.7) 13 ( 4.3) Injection site erythema 1 (
Slide 20: A Highly Differentiated Neuromodulator Product
DaxibotulinumtoxinA for Injection*1 Molecular weight 150 kDa 900 kDa7 ~400 kDa 150 kDa Cervical Dystonia dose 125U, 250U 236U 500U 120U, 240U Core neurotoxin amount** 0.56 ng, 1.12 ng 1.96 ng6 2.69 ng6 0.484 ng6, 0.968 ng6 Free of accessory proteins ✓ ✓ Proprietary peptide excipient technology ✓ No
Slide 21: Phase 3 Top-Line Results Summary
Phase 3 Top-Line Results Demonstrated that DaxibotulinumtoxinA for Injection, at either 125U or 250U, was an effective and generally well-tolerated treatment for reducing the signs and symptoms for cervical dystonia with up to a median duration of 24 weeks. DaxibotulinumtoxinA appeared to be general
Slide 22: Thank You to Patients, Investigators, CROs & Revance Team
Thank You to Patients, Investigators, CROs & Revance Team
Slide 23: Revance Therapeutics
REVANCE THERAPEUTICS & revance
Slide 24: Duration Is Critically Important to Physicians and Patients
Both physicians and patients consider duration a critically important factor with botulinum toxin treatment.1 1. Timothy Corcoran Flynn , Examining Duration of Effect in Facial Aesthetic Applications , Am J Clin Dermatol 2010; . DaxibotulinumtoxinA For Injection Has Demonstrated Long Duration in Tho
Slide 25: Therapeutic Opportunity: Cervical Dystonia Market
Market of BoNT use in Cervical Dystonia estimated $340M worldwide.1 There are 12 Approved Therapeutic Indications for Botulinum Toxin Type A in the U.S. and hundreds of potential indications3 $2.3 Billion2 Global Therapeutics Neuromodulator Revenues 29% CHRONIC MIGRAINE 51% MUSCLE MOVEMENT/ PAIN 1%
Slide 26: Cervical Dystonia Is One of Three Muscle Movement and Pain Indications
Cervical Dystonia Is One of Three Muscle Movement and Pain Indications In Therapeutics Revance is Currently Pursuing ADULT UPPER LIMB SPASTICITY PLANTAR FASCIITIS ~$391M Global Spasticity Opportunity1 Typically treated by neurologists. Phase 2 Placebo-Controlled Study Fully Enrolled. Topline results
Slide 27: Entering Attractive, Growing Markets Totaling >$6 Billion
Entering Attractive, Growing Markets Totaling >$6 Billion Today $8.5B by 2025 $5.1B1 today GLOBAL NEUROMODULATORS $2B by 2025 $1.1B2 today U.S. HYALURONIC ACID DERMAL FILLERS $700M by 2025 $ 500M3 today U.S. AESTHETICS FINTECH PLATFORM Decision Resources Group Therapeutic Botulinum Toxin Market Anal
Slide 28: Thank You
7555 Gateway Boulevard Newark, California 94560 +1 (510) 742-3400 Thank You.
Revance Therapeutics — Technical Presentation (October 2020) on 6ix